Vitreous and aqueous penetration of orally administered moxifloxacin in humans.
Kampougeris
G
G
Antoniadou
A
A
D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics*; D001082:Aqueous Humor / Q000378:metabolism*; D001372:Aza Compounds / Q000493:pharmacokinetics*; D009877:Endophthalmitis / Q000188:drug therapy; D024841:Fluoroquinolones; D006801:Humans; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D011804:Quinolines / Q000493:pharmacokinetics*; D013212:Staphylococcus epidermidis / Q000187:drug effects; D014822:Vitreous Body / Q000378:metabolism*
D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin